These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26820147)

  • 1. Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?
    Garattini L; Curto A; Freemantle N
    Pharmacoeconomics; 2016 May; 34(5):423-6. PubMed ID: 26820147
    [No Abstract]   [Full Text] [Related]  

  • 2. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L; McGowan B; Bennett K; Barry M
    Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
    Alifrangis C; Krell J; Stebbing J
    Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
    [No Abstract]   [Full Text] [Related]  

  • 9. Foreign free riders and the high price of US medicines.
    Light DW; Lexchin J
    BMJ; 2005 Oct; 331(7522):958-60. PubMed ID: 16239695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economist Conferences Ninth Annual Pharmaceuticals Conference. 12-13 February 2003, London, UK.
    Mayfield R
    IDrugs; 2003 Apr; 6(4):337-9. PubMed ID: 12839014
    [No Abstract]   [Full Text] [Related]  

  • 12. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
    Golec J; Vernon JA
    Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing medicines: theory and practice, challenges and opportunities.
    Gregson N; Sparrowhawk K; Mauskopf J; Paul J
    Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
    Timur A; Picone G
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'The pros and cons of a single euro-price for drugs' and 'the economics of parallel trade'.
    Rovira J
    Pharmacoeconomics; 1998 Jul; 14(1):135-7. PubMed ID: 10182191
    [No Abstract]   [Full Text] [Related]  

  • 17. Pricing schemes for new drugs: a welfare analysis.
    Levaggi R
    Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulating the pharmaceutical industry. Authors seem to have misunderstood pharmaceutical price regulation scheme.
    Read P
    BMJ; 1998 Jan; 316(7126):226; author reply 228. PubMed ID: 9468700
    [No Abstract]   [Full Text] [Related]  

  • 20. [The aspects of pricing policy in Azerbaijan pharmaceutical sector].
    Dzhalilova KI; Alieva KIa
    Georgian Med News; 2012 Jan; (202):48-53. PubMed ID: 22392783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.